Dorsey & Whitney Trust CO LLC Has $8.66 Million Holdings in Solventum Co. (NYSE:SOLV)

Dorsey & Whitney Trust CO LLC cut its holdings in Solventum Co. (NYSE:SOLV) by 0.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 131,082 shares of the company’s stock after selling 184 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Solventum were worth $8,659,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SOLV. Generali Investments CEE investicni spolecnost a.s. bought a new position in Solventum during the fourth quarter worth $337,000. Machina Capital S.A.S. boosted its position in Solventum by 21.8% during the fourth quarter. Machina Capital S.A.S. now owns 3,905 shares of the company’s stock worth $258,000 after purchasing an additional 700 shares during the period. Andra AP fonden acquired a new stake in shares of Solventum during the fourth quarter worth $1,302,000. E Fund Management Co. Ltd. acquired a new stake in shares of Solventum during the fourth quarter worth $334,000. Finally, Candriam S.C.A. acquired a new stake in shares of Solventum during the fourth quarter worth $517,000.

Solventum Stock Up 2.9 %

Shares of NYSE SOLV opened at $77.96 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company has a market cap of $13.47 billion and a price-to-earnings ratio of 28.35. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The stock has a 50-day moving average price of $73.65 and a two-hundred day moving average price of $70.55.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SOLV. Mizuho lifted their target price on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. Morgan Stanley lifted their target price on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday. The Goldman Sachs Group lifted their target price on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Piper Sandler lifted their target price on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. Finally, Wells Fargo & Company boosted their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.